In a patient on apixaban (Eliquis) scheduled for elective eye‑tumor removal, how long should the medication be stopped before surgery based on renal function, is heparin bridging needed, and when can it be restarted after the procedure?

Perioperative Management of Apixaban for Eye Tumor Removal

Direct Recommendation

For elective eye tumor removal, stop apixaban 2 days before surgery (skip 4 doses) if renal function is normal, 3 days before if creatinine clearance is 30-50 mL/min, and restart at least 24 hours postoperatively once hemostasis is confirmed; bridging anticoagulation is not needed. 1, 2, 3

---

Preoperative Discontinuation Timeline

Bleeding Risk Classification

• Eye tumor removal is classified as a high bleeding-risk procedure due to the highly vascular nature of ocular tissue and the catastrophic consequences of intraocular hemorrhage. 1, 2

Discontinuation Based on Renal Function

For patients with normal or mild renal impairment (CrCl ≥50 mL/min):

• Stop apixaban 2 days (48 hours) before surgery, which corresponds to skipping 4 doses of the twice-daily regimen. 1, 2
• This allows 4-5 half-lives to elapse, achieving minimal residual anticoagulant effect (12-25%). 1, 2

For patients with moderate renal impairment (CrCl 30-50 mL/min):

• Stop apixaban 3 days (72 hours) before surgery, which corresponds to skipping 6 doses. 1, 3
• The prolonged half-life in moderate renal impairment (approximately 10-12 hours) necessitates this extended interruption. 1, 3

For patients with severe renal impairment (CrCl 15-29 mL/min):

• Stop apixaban 4 days (96 hours) before surgery, skipping 8 doses. 3
• Consider measuring drug-specific anti-Xa levels to confirm adequate clearance if available. 3

Supporting Evidence

• The 2022 American College of Chest Physicians guideline recommends 1-day interruption for low-to-moderate bleeding risk and 2-day interruption for high bleeding risk procedures in patients with normal renal function. 1
• However, the older 2012 Blood guideline provides more conservative recommendations (2-3 days for high-risk procedures), which may be more appropriate for ophthalmic surgery given the devastating consequences of bleeding. 1, 2
• A 2022 prospective cohort study (ADIOS) demonstrated that 94% of patients achieved apixaban concentrations ≤30 ng/mL with a median interruption of 76 hours, supporting the safety of 2-3 day interruption. 4

---

Bridging Anticoagulation

Bridging with heparin or low-molecular-weight heparin is NOT recommended. 1, 3

• The rapid offset and onset of apixaban (half-life 7-8 hours) eliminates the need for bridging therapy. 1, 2
• Bridging increases major bleeding risk three-fold without reducing thromboembolic events. 3
• The 24-72 hour interruption period does not require substitution with short-acting anticoagulants. 1, 3

---

Postoperative Resumption

Timing of Restart

For high bleeding-risk procedures like eye tumor removal:

• Resume apixaban at least 24 hours after surgery, but preferably 48-72 hours postoperatively once adequate hemostasis is confirmed. 1, 2, 3
• The rapid onset of action (peak effect at 1-3 hours) requires cautious administration to avoid precipitating bleeding if hemostasis is incomplete. 1, 3

Practical Considerations

• Ensure there is no active bleeding or oozing from the surgical site before restarting. 1, 3
• For patients at very high thromboembolism risk, consider mechanical prophylaxis (compression devices) during the delay period. 3
• Resume at the usual therapeutic dose (typically 5 mg twice daily); dose reduction is generally not necessary unless specifically indicated by renal function or other factors. 3

---

Critical Pitfalls to Avoid

Do not rely on standard coagulation tests (INR, aPTT) to guide timing:

• These tests do not reliably reflect apixaban activity and should not be used for surgical clearance. 2, 3
• If laboratory confirmation is needed, anti-Xa activity correlates well with apixaban exposure. 2, 3

Do not resume apixaban too early after high-risk surgery:

• Premature resumption (within 12-24 hours) can precipitate major bleeding due to rapid peak anticoagulant effect. 3, 5
• Clinical trials demonstrate that delaying the first postoperative dose for at least 6 hours improves safety. 5

Do not extend interruption unnecessarily beyond recommended timeframes:

• Excessively long interruption (>3-4 days for normal renal function) increases thromboembolic risk without additional bleeding benefit. 1, 4

Mandatory renal function assessment:

• Always check creatinine clearance before determining the discontinuation timeline, as moderate-to-severe impairment significantly prolongs apixaban elimination. 1, 2, 3
• Patients with declining renal function require extended preoperative interruption even if baseline function was acceptable. 3

---

Algorithm Summary

1. Assess renal function (calculate CrCl). 1, 2, 3
2. Classify bleeding risk (eye tumor removal = high risk). 1, 2
3. Stop apixaban:
   • CrCl ≥50: 2 days before surgery 1, 2
   • CrCl 30-50: 3 days before surgery 1, 3
   • CrCl 15-29: 4 days before surgery 3
4. No bridging anticoagulation. 1, 3
5. Resume apixaban 24-72 hours postoperatively once hemostasis is confirmed. 1, 2, 3